Prognostic factors for survival after transarterial chemoembolization combined with microwave ablation for hepatocellular carcinoma

Table 1 Characteristics of the patients included in this study n (%)

Characteristic	Patients
Age (yr)
≤ 40	17 (19.8)
41-50	16 (18.6)
51-60	29 (33.7)
> 60	24 (27.9)
Gender
Male	76 (88.3)
Female	10 (11.7)
BCLC stage
A	4 (4.7)
B	60 (69.7)
C	22 (25.6)
Tumor size (TS)
Small HCC (TS ≤ 3 cm)	13 (15.1)
Nodular type (3 cm < TS ≤ 5 cm)	32 (37.2)
Massive type (5 cm < TS ≤ 10 cm)	11 (12.8)
Huge type (10 cm < TS)	30 (34.9)
PVTT
None	67 (77.9)
Branch type	10 (11.6)
Trunk type	9 (10.5)
Child-Pugh class
A	62 (72.0)
B	24 (28.0)
ECOG score
0	11 (12.8)
1	45 (52.3)
≥ 2	30 (34.9)
AFP
Negative ( ≤ 20 μg/L)	31 (36.0)
Positive (> 20 μg/L)	55 (64.0)
HBsAg
Without	45 (52.3)
With	41 (47.7)
AVF
Without	68 (79.0)
With	18 (21.0)
MWA times
Once	35 (40.1)
Twice	24 (27.9)
≥ Triple	27 (32.0)
TACE times
Once	19 (22.1)
Twice	16 (18.6)
Triple	21 (24.4)
≥ Triple	30 (34.9)
Targeted drug
Without	22 (25.6)
With	64 (74.4)

TACE: Transarerial chemoembolization; MWA: Microwave ablation; BCLC: Barcelona Clinic Liver Cancer; ECOG: Eastern Cooperative Oncology Group; AVF: Arterio-venous fistula; TS: Tumor size; PVTT: Portal vein tumor thrombus; HCC: Hepatocellular carcinoma; AFP: Alpha fetal protein; HBsAg: Serum hepatitis B surface antigen.